[
    [
        {
            "time": "2021-06-30",
            "original_text": "复星医药：作为国内首个上市的个性化细胞治疗产品，奕凯达为二线以后的淋巴瘤患者带来了持续缓解的可能性",
            "features": {
                "keywords": [
                    "复星医药",
                    "个性化细胞治疗",
                    "奕凯达",
                    "淋巴瘤",
                    "持续缓解"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：作为国内首个上市的个性化细胞治疗产品，奕凯达为二线以后的淋巴瘤患者带来了持续缓解的可能性",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-06-30",
            "original_text": "复星医药：截至2021年6月30日，集团已有共计19个已通过或视为通过仿制药一致性评价的产品在五批药品集采招标中中标",
            "features": {
                "keywords": [
                    "复星医药",
                    "仿制药",
                    "一致性评价",
                    "药品集采",
                    "中标"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：截至2021年6月30日，集团已有共计19个已通过或视为通过仿制药一致性评价的产品在五批药品集采招标中中标",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-09-14",
            "original_text": "复星医药(02196)：复宏汉霖拟为其控股子公司汉霖制药不超3亿元债务提供担保 大额借贷担保",
            "features": {
                "keywords": [
                    "复星医药",
                    "复宏汉霖",
                    "汉霖制药",
                    "债务担保",
                    "大额借贷"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药(02196)：复宏汉霖拟为其控股子公司汉霖制药不超3亿元债务提供担保 大额借贷担保",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-09-14",
            "original_text": "复星医药：本集团实际对外担保金额按2021年9月14日汇率折合人民币约203.75亿元 大额借贷担保",
            "features": {
                "keywords": [
                    "复星医药",
                    "对外担保",
                    "大额借贷",
                    "汇率"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药：本集团实际对外担保金额按2021年9月14日汇率折合人民币约203.75亿元 大额借贷担保",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        }
    ]
]